Physician profile
Mark A Evans
NPI 1164463832
$1,927.03
in general payments reported to CMS, 2019-2025
12 companies · $68.59 in 2025
The $68.59 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.66 · 2020: $16.53 · 2022: $156 · 2023: $65.00 · 2024: $1,530 · 2025: $68.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,128 · Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,127.60 |
| Food and Beverage | $536.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,557.41 | 2023-2025 | Watchman Access System, Watchman Flx |
| Heartflow, INC. | $126.33 | 2022 | |
| Pfizer INC. | $49.95 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $41.67 | 2024 | Arcalyst |
| Medtronic, INC. | $26.93 | 2023 | Corevalve Evolut R |
| Cook Medical LLC | $23.98 | 2019 | |
| Daxor Corporation | $22.41 | 2024 | Bva-100 |
| Abbott Laboratories | $16.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.77 | 2022 | |
| Genzyme Corporation | $15.60 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.